1 Nov 2022
Apex Labs Granted Approval for North America’s First Take Home Psilocybin Clinical Trial
Author: admintech | Filed under: Press ReleaseAPEX-002-A01-02 will evaluate the safety and efficacy of APEX-52 low dose, multi-dose synthetic psilocybin drug product in treating depression in Veterans with PTSD VANCOUVER, BC, Nov. 1, 2022 /PRNewswire/ – Apex Labs Ltd. (“APEX” or the “Company”), a pharmaceutical company optimizing the…